Skip to main content

Novo-Nordisk Value Stock - Dividend - Research Selection

Novo-Nordisk A/S

ISIN: DK0060534915, WKN: A1XA8R

Market price date: 26.01.2022
Market price: 612,91 DKK


Novo-Nordisk A/S Fundamental data and company key figures of the share

Annual reports in DKK
Key figures 26-05-2021
Cash flow
Net operating cash flow 51.951.000.000
Capital Expenditures -22.081.000.000
Free cash flow 29.870.000.128
Balance sheet
Total Equity 63.325.000.000
Liabilities & Shareholders equity 144.922.000.000
Income statement
Net income 42.138.000.000
Eps (diluted) 18,008
Diluted shares outstanding 2.340.000.000
Net sales/revenue 126.946.000.000

Fundamental ratios calculated on: 26-01-2022

Ratios
Key figures 26-01-2022
Cash flow
P/C 28,17
   
P/FC 48,02
Balance sheet
ROI29,08
ROE43,70
Income statement
P/E34,04
Div. Yield1,46%
P/B23,11
P/S11,30


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolNVO
Market Capitalization207.321.628.672,00 USD
CountryDenmark
IndicesSTOXX EUROPE 600,MSCI World Index
SectorsPharmaceuticals
Raw Data SourceIFRS in Millionen DKK
Stock Split2014-01-10,5.0000/1.0000; 2014-01-09,5.0000/1.0000; 2007-12-18,2.0000/1.0000; 2007-12-17,2.0000/1.0000; 2001-04-12,5.0000/2.0000; 2001-04-11,5.0000/2.0000; 1994-04-19,4.0000/1.0000; 1994-04-18,4.0000/1.0000
Internetwww.novonordisk.com


Description of the company

Novo Nordisk A/S is a Denmark-based company engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company reports two business segments: Diabetes care and Biopharmaceuticals. The Diabetes care division offers a range of diabetes products, including insulin pens and needles, such as FlexPen, NovoPen and FlexTouch, among others, and diabetes medicine, such as insulin- and non-insulin treatment, among others. The Biopharmaceuticals division provides products within the areas of haemophilia, growth hormone therapy, hormone replacement therapy, inflammation therapy and other therapy areas. As of December 31, 2012, the Company marketed its products in five reported geographical regions, namely North America, Europe, Region China, Japan and Korea, as well as International Operations. The Company wholly owns over 70 subsidiaries, such as Novo Nordisk Pharma GmbH, Novo Nordisk Canada Inc., Novo Nordisk Region Japan & Korea A/S, among others.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.novonordisk.com


NEWS


Private Ocean, LLC Buys Regal Rexnord Corp, T-Mobile US Inc, Vanguard Total Bond Market ETF, ...

2022-01-25
San Rafael, CA, based Investment company Private Ocean, LLC (Current Portfolio) buys Regal Rexnord Corp, T-Mobile US Inc, Vanguard Total Bond Market ETF, WisdomTree U.S.

DDD Partners, LLC Buys Intel Corp, Novo Nordisk A/S, Broadcom Inc, Sells Adaptive ...

2022-01-24
Investment company DDD Partners, LLC (Current Portfolio) buys Intel Corp, Novo Nordisk A/S, Broadcom Inc, DocuSign Inc, Atlas Corp, sells Adaptive Biotechnologies Corp, Editas Medicine Inc, Magna International Inc, Activision Blizzard Inc, Gentex Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, DDD Partners, LLC.

Novo Nordisk A/S – Share repurchase programme

2022-01-24
Novo Nordisk A/S – Share repurchase programme Bagsværd, Denmark, 24 January 2022 – On 5 November 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period

Novo-Nordisk Becomes Oversold (NVO)

2022-01-24
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which m

What to watch today: Wall Street to open lower after Nasdaq's worst week since March 2020

2022-01-24
U.S. stock futures indicated more losses to start the new week following the Nasdaq's and the S&P 500's worst weeks since March 2020.

Stocks making the biggest moves in the premarket: Kohl's, Snap, Peloton and more

2022-01-24
The stocks making the biggest moves in premarket trading include Kohl's, Snap, Peloton, and more.

Earnings playbook: A complete guide to this week's reports, including the first of tech

2022-01-23
Microsoft, Tesla and Apple will release quarterly results, alongside a handful of other tech firms. McDonald's and Boeing will also offer updates.

Nicholas Ward's Dividend Growth Portfolio: 2021 Full Year Update

2022-01-22
My passive income was up 20.30% in December. This pushed my full-year dividend growth up to 14.99%. Find more about my portfolio here.

Novo-Nordisk Breaks Below 200-Day Moving Average - Notable for NVO

2022-01-21
In trading on Friday, shares of Novo-Nordisk AS (Symbol: NVO) crossed below their 200 day moving average of $95.22, changing hands as low as $95.13 per share. Novo-Nordisk AS shares are currently trading down about 0.3% on the day. The chart below shows the one year performan

Markets are expected to remain on edge as the Fed meets in the week ahead

2022-01-21
The Federal Reserve's meeting trumps everything else for markets in the week ahead, as investors await any new clues on its plans to raise interest rates.